당뇨병성 망막증 시장 보고서 : 유형별, 치료 유형별, 최종 사용자별, 지역별(2025-2033년)

The global diabetic retinopathy market size reached USD 8.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5% during 2025-2033. The surging prevalence of diabetes, rising demand for effective treatments, and growing awareness regarding early diagnosis and treatment of diabetic retinopathy represent some of the key factors driving the market.

Diabetic retinopathy (DR) is a common complication of diabetes that affects the retina, the part of the eye that senses light and sends signals to the brain. It occurs when high blood sugar levels damage the small blood vessels in the retina, causing them to leak or become blocked. This can lead to vision loss or blindness if left untreated. There are two main types of diabetic retinopathy, namely non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Its diagnosis involves a comprehensive eye exam, which may include tests such as fluorescein angiography and optical coherence tomography. These tests can help to identify the presence and severity of DR, allowing for early intervention and treatment. Currently, there are several treatment options available for DR, including the use of intraocular steroid injections, laser treatment, and vitrectomy. Intraocular steroid injections can help to reduce inflammation and swelling in the eye, while laser treatment can be used to seal leaking blood vessels and prevent further damage to the retina. In more severe cases, a vitrectomy may be necessary to remove blood or scar tissue from the eye.

Diabetic Retinopathy Market Trends:

The global diabetic retinopathy market is witnessing significant growth, primarily driven by the rising prevalence of diabetes and the increasing geriatric population. In line with this, key players are actively working to develop new therapeutic solutions for diabetic retinopathy, which is bolstering market growth. Apart from this, the development of new drugs and therapies, such as anti-VEGF agents and sustained-release implants, has also significantly contributed to market growth. Additionally, the escalating adoption of telemedicine and artificial intelligence (AI) in the diagnosis and treatment of diabetic retinopathy is driving the market growth. The rising demand for effective treatments due to the growing awareness of diabetic retinopathy and its potential consequences is acting as another growth-inducing factor. Furthermore, the surging awareness regarding early diagnosis and treatment of diabetic retinopathy, coupled with advancements in ophthalmic technology, are fueling the market growth. Other factors, such as increasing healthcare expenditure, the implementation of various government initiatives to improve eye care services, and the availability of favorable reimbursement policies, are propelling the market growth.

Key Market Segmentation:

Type Insights:

• Proliferative Diabetic Retinopathy
• Non-proliferative Retinopathy

Treatment Type Insights:

• Anti VEGF Drugs
• Steroid Implants
• Laser Surgeries
• Vitrectomy

End-User Insights:

• Hospitals and Pharmacies
• Eye Clinics
• Ambulatory Surgical Centres (ASCs)
• Others

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. As per the report, North America dominates the market. Some of the factors accelerating the North America diabetic retinopathy market include the increasing prevalence of diabetes, growing awareness about diabetic retinopathy, and advancements in diagnostic and treatment technologies.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global diabetic retinopathy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global diabetic retinopathy market performed so far, and how will it perform in the coming years ?
• What are the drivers, restraints, and opportunities in the global diabetic retinopathy market ?
• What is the impact of each driver, restraint, and opportunity on the global diabetic retinopathy market ?
• What are the key regional markets ?
• Which countries represent the most attractive diabetic retinopathy market ?
• What is the breakup of the market based on the type ?
• Which is the most attractive type in the diabetic retinopathy market ?
• What is the breakup of the market based on the treatment type ?
• Which is the most attractive treatment type in the diabetic retinopathy market ?
• What is the breakup of the market based on the end-user ?
• Which is the most attractive end-user in the diabetic retinopathy market ?
• What is the competitive structure of the global diabetic retinopathy market ?
• Who are the key players/companies in the global diabetic retinopathy market ?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Diabetic Retinopathy Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Proliferative Diabetic Retinopathy
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Non-proliferative Retinopathy
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Treatment Type

• 7.1 Anti VEGF Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Steroid Implants
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Laser Surgeries
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Vitrectomy
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End-User

• 8.1 Hospitals and Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Eye Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Ambulatory Surgical Centres (ASCs)
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Alimera Sciences
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
  • 13.3.2 Allergan Plc
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Ampio Pharmaceuticals
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
  • 13.3.4 Bayer Healthcare
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 BCN Peptides
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Genentech
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 SWOT Analysis
  • 13.3.7 Kowa Group
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 Novartis AG
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 Regeneron Pharmaceuticals Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Sirnaomics Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio